Analysts expect Clorox Co (NYSE:CLX) to report $1.53 billion in sales for the current quarter, according to Zacks. Five analysts have issued estimates for Clorox’s earnings, with the lowest sales estimate coming in at $1.52 billion and the highest estimate coming in at $1.55 billion. Clorox posted sales of $1.50 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 2%. The business is scheduled to announce its next earnings report on Wednesday, November 7th.

On average, analysts expect that Clorox will report full-year sales of $6.34 billion for the current year, with estimates ranging from $6.30 billion to $6.37 billion. For the next fiscal year, analysts anticipate that the company will post sales of $6.52 billion per share, with estimates ranging from $6.48 billion to $6.53 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Clorox.

Clorox (NYSE:CLX) last posted its earnings results on Thursday, August 2nd. The company reported $1.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.08. Clorox had a return on equity of 103.18% and a net margin of 13.44%. The business had revenue of $1.69 billion during the quarter, compared to analyst estimates of $1.72 billion. During the same quarter last year, the firm earned $1.53 earnings per share. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year.

CLX has been the subject of a number of recent research reports. BMO Capital Markets reiterated a “buy” rating and issued a $153.00 target price on shares of Clorox in a research note on Friday, August 3rd. Goldman Sachs Group lowered Clorox from a “neutral” rating to a “sell” rating and lowered their target price for the company from $127.00 to $112.00 in a research note on Tuesday, July 17th. They noted that the move was a valuation call. UBS Group initiated coverage on Clorox in a research note on Wednesday, July 18th. They issued a “sell” rating and a $110.00 target price for the company. Bank of America increased their target price on Clorox from $130.00 to $140.00 and gave the company a “neutral” rating in a research note on Monday, July 16th. Finally, ValuEngine upgraded Clorox from a “sell” rating to a “hold” rating in a research note on Tuesday, June 26th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $130.42.

In other Clorox news, EVP Linda J. Rendle sold 382 shares of the firm’s stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $148.32, for a total transaction of $56,658.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael R. Costello sold 9,265 shares of the firm’s stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $140.02, for a total value of $1,297,285.30. Following the sale, the senior vice president now owns 34,293 shares of the company’s stock, valued at approximately $4,801,705.86. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,268 shares of company stock valued at $4,196,686. 1.00% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Oppenheimer Asset Management Inc. grew its stake in Clorox by 1.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 23,638 shares of the company’s stock valued at $3,197,000 after purchasing an additional 383 shares in the last quarter. Global X Management Co LLC grew its stake in Clorox by 6.0% during the 2nd quarter. Global X Management Co LLC now owns 6,899 shares of the company’s stock valued at $933,000 after purchasing an additional 391 shares in the last quarter. Advisor Partners LLC grew its stake in Clorox by 10.8% during the 2nd quarter. Advisor Partners LLC now owns 4,172 shares of the company’s stock valued at $564,000 after purchasing an additional 408 shares in the last quarter. First Midwest Bank Trust Division grew its stake in Clorox by 2.5% during the 2nd quarter. First Midwest Bank Trust Division now owns 17,026 shares of the company’s stock valued at $2,303,000 after purchasing an additional 412 shares in the last quarter. Finally, Texas Yale Capital Corp. lifted its holdings in Clorox by 3.5% during the 2nd quarter. Texas Yale Capital Corp. now owns 12,430 shares of the company’s stock worth $1,681,000 after buying an additional 415 shares during the last quarter. Hedge funds and other institutional investors own 78.14% of the company’s stock.

CLX stock opened at $151.38 on Friday. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 3.15. Clorox has a 1 year low of $113.57 and a 1 year high of $152.39. The stock has a market capitalization of $19.32 billion, a PE ratio of 26.37, a P/E/G ratio of 3.12 and a beta of 0.35.

Clorox announced that its Board of Directors has authorized a share repurchase plan on Thursday, May 24th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to reacquire up to 12.6% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its shares are undervalued.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

See Also: How do investors use RSI to grade stocks?

Get a free copy of the Zacks research report on Clorox (CLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.